Skip to main content
  • Donate Blood (Opens in a new tab/window)
  • About NBA
  • News and updates
  • Resources
  • BloodPortal login (Opens in a new tab/window)
Logo image Logo image
  • Blood Products
    • Blood Products
    • National Product Price List
    • Fresh Blood Products
    • Albumin Products
    • Clotting Factor and Other Products
    • Immunoglobulin Products
      • Immunoglobulin Usage and Data
      • Intravenous Immunoglobulin (IVIg)
      • Subcutaneous Immunoglobulin (SCIg)
      • Normal Human Immunoglobulin (NHIg)
      • Hyperimmune Immunoglobulin Products
    • Access and Ordering
      • BloodSTAR for Ig Products
      • BloodSTAR Registration Form
      • BloodNet for Blood Products from Lifeblood
      • BloodNet System Interface
      • Frequently Asked Questions
    • Blood Product Management
      • Inventory Management
      • Blood Product Wastage
      • Blood and Inventory Management Resources
      • Case Studies
      • Single Unit Transfusion Guide
  • Supply System
    • Supply System
    • Managing Blood Supply
      • Risk Management
      • National Stewardship Program
      • Blood Product Labelling
    • Governance for Immunoglobulin Products
      • National Immunoglobulin Governance Committees
      • Criteria for Immunoglobulin Products
    • Suppliers and Commercial Supply Contracts
      • Fresh Blood Product Supply and Lifeblood
      • Plasma and Recombinant Product Supply
      • Imported Product Supply
      • Red Cell Diagnostic Product Supply
    • Australian Health Provider Access to Blood and Blood Products
    • Overseas Supply of Blood Products
  • Clinical Guidance
    • Clinical Guidance
      • Rh D Ig Guideline (Opens in a new tab/window)
      • PBM Guidelines (Opens in a new tab/window)
    • National Standards
    • Immunoglobulin
    • Patient Blood Management
      • Patient Blood Management (PBM) Resources
    • Transfusion-related Adverse Events
    • Bleeding Disorders
      • Australian Bleeding Disorders Registry (ABDR)
    • eLearning Courses
    • Public Consultations
    • Patient Blood Management Guidelines (Opens in a new tab/window)
  • Data and Research
    • Data and Research
    • Data and Reporting
    • Research Funding Program
      • Successful Grant Rounds
  • Patient Information
    • Patient information
      • Applying for overseas supply of blood products
    • Bleeding disorders
    • Blood disorders
    • Travelling with blood products
    • MyABDR app and the ABDR

Search

  • Donate Blood (Opens in a new tab/window)
  • About NBA
  • News and updates
  • Resources
  • BloodPortal login (Opens in a new tab/window)
  • Blood Products
    • Blood Products
    • National Product Price List
    • Fresh Blood Products
    • Albumin Products
    • Clotting Factor and Other Products
    • Immunoglobulin Products
      • Immunoglobulin Usage and Data
      • Intravenous Immunoglobulin (IVIg)
      • Subcutaneous Immunoglobulin (SCIg)
      • Normal Human Immunoglobulin (NHIg)
      • Hyperimmune Immunoglobulin Products
    • Access and Ordering
      • BloodSTAR for Ig Products
      • BloodSTAR Registration Form
      • BloodNet for Blood Products from Lifeblood
      • BloodNet System Interface
      • Frequently Asked Questions
    • Blood Product Management
      • Inventory Management
      • Blood Product Wastage
      • Blood and Inventory Management Resources
      • Case Studies
      • Single Unit Transfusion Guide
  • Supply System
    • Supply System
    • Managing Blood Supply
      • Risk Management
      • National Stewardship Program
      • Blood Product Labelling
    • Governance for Immunoglobulin Products
      • National Immunoglobulin Governance Committees
      • Criteria for Immunoglobulin Products
    • Suppliers and Commercial Supply Contracts
      • Fresh Blood Product Supply and Lifeblood
      • Plasma and Recombinant Product Supply
      • Imported Product Supply
      • Red Cell Diagnostic Product Supply
    • Australian Health Provider Access to Blood and Blood Products
    • Overseas Supply of Blood Products
  • Clinical Guidance
    • Clinical Guidance
      • Rh D Ig Guideline
      • PBM Guidelines
    • National Standards
    • Immunoglobulin
    • Patient Blood Management
      • Patient Blood Management (PBM) Resources
    • Transfusion-related Adverse Events
    • Bleeding Disorders
      • Australian Bleeding Disorders Registry (ABDR)
    • eLearning Courses
    • Public Consultations
    • Patient Blood Management Guidelines
  • Data and Research
    • Data and Research
    • Data and Reporting
    • Research Funding Program
      • Successful Grant Rounds
  • Patient Information
    • Patient information
      • Applying for overseas supply of blood products
    • Bleeding disorders
    • Blood disorders
    • Travelling with blood products
    • MyABDR app and the ABDR

Contracts with suppliers of blood and blood products

  • Home
  • Contracts with suppliers of blood and blood products

Maintaining security of supply also requires the National Blood Authority (NBA) to manage contracts with suppliers of blood and blood products. Contracts are developed in accordance with the Commonwealth Procurement Rules, and managed in accordance with best practice guidance for contract management, including the guideline from the Australian National Audit Office on Developing and Managing Contracts.

The NBA currently manages 15 blood and blood product supply contracts and arrangements.

The contracts managed by the NBA include:

  • Fresh Blood Product Procurement - Australia's fresh blood component requirements through the Deed of Agreement with the Australian Red Cross Society.
  • Plasma and Recombinant Product Procurement - Australia's plasma product and recombinant product requirements through:
  • the National Fractionation Agreement for Australia (NaFAA) and contracts for the provision of imported immunoglobulin (Ig), imported recombinant factors VIIa, VIII, IX, and XIII, and other imported plasma and recombinant products
  • Red Cell Diagnostic Products Procurement - Australia’s requirements for red cell diagnostic products.

Health provider verification of supplier performance

Since 2003 the NBA has undertaken periodic sample-based Goods Ordering and Receipt Verification (GORV) audits of the suppliers under national contracts administered by the agency. The audits are fundamental to the NBA’s national contract management role, and provide verification of supplier invoicing.

During the GORV audit at the end of each quarter, the NBA asks relevant health providers to confirm orders and receipt of product from the health providers’ administrative records.

It is important to emphasise that this process is not an audit of health providers but focuses only on supplier performance against national contract requirements.

Read the detail

The NBA manages national contracts for the supply of blood products to the Australian health system. These contracts include performance obligations on suppliers on matters such as product ordering, distribution and delivery. Non compliance with these obligations and performance measures may result in financial consequences for suppliers.

Suppliers are required to retain documentary records to substantiate all orders and deliveries for the supply of products funded under the national blood arrangements.

Goods Order Receipt Verification (GORV) audits

Since 2003 the NBA has undertaken periodic sample based Goods Ordering and Receipt Verification (GORV) audits of the suppliers under national contracts administered by the agency. The audits are fundamental to the NBA’s national contract management role, and provide verification of supplier invoicing.

All GORV audits are conducted retrospectively and examine documentation held by suppliers that verify the following against a small sample of invoices in a particular period:

  • An order was placed correctly; and
  • Ordered products were delivered in full and on time.

Health provider verification of supplier performance

Until recently, GORV audits have not included any independent verification of the order or delivery documentation suppliers provide the NBA.

In July 2013, the NBA commenced a process of requesting verification from records kept by the relevant ordering health provider (whether a hospital, clinic, other health service or individual clinician) to confirm that an order was placed, and that product was received, as per the supplier’s documentation.

In this process, during the GORV audit at the end of each quarter, the NBA asks relevant health providers to confirm orders and receipt of product from the health providers’ administrative records (e.g. from ABDR, BloodNET, Supplier Reports, consignment notes, delivery dockets).

The NBA values the active involvement of health providers in this process as it will provide an opportunity for feedback on supplier performance and improve service delivery.

It is important to emphasise that this process is not an audit of health providers but focuses only on supplier performance against national contract requirements.

Procurement process

The NBA has developed a robust approach to tendering and contracting for blood products, reflecting both the policy objectives of governments under the National Blood Agreement, and the policies and requirements of the Australian Government procurement framework.

How these objectives are achieved depends on the product and the supply arrangements in question. The NBA relies on regulation by the Therapeutic Goods Administration to address the major policy aim of safety. The policy aim of affordability is addressed through various procurement mechanisms such as competitive tendering, price benchmarking and other specific negotiation approaches. The policy aims of adequacy and security of supply are addressed through a range of measures such as primary and contingency supply arrangements, inventory and inventory reserve requirements, and an integrated regime of supply and contract risk protections.

The NBA undertakes extensive preparations for tender processes. Within the year before releasing tenders this process will generally include:

  • gathering information on the global market
  • obtaining information and customer feedback from suppliers and stakeholders on important issues such as:
    • the level of satisfaction with the current supply arrangements
    • the products needed and the availability of product choice
    • the tender period preferred by suppliers and the potential for product enhancements during that time
    • the extent of competition for supply of specific products
    • price considerations
  • reviewing the current arrangements to identify where improvements might be gained (e.g. security of supply, safety and value for money)
  • using our knowledge of normal supply chain and commercial arrangements of suppliers to design arrangements that suppliers can achieve and sustain.

Customer feedback on commercial supply contracts

Feedback on supply arrangements managed by the NBA should be directed firstly to the relevant supplier. Visit Customer Feedback on Commercial Supply Contracts for more information on the NBA established customer feedback mechanisms for commercial supply contracts.

Last updated: 27 Mar 2024

Back to top

The National Blood Authority acknowledges the Traditional Owners and Custodians of Country throughout Australia, and their continuing connection to land, water and community. We pay our respects to the people, the cultures and the elders past, present and emerging.

National Blood Authority

  • About the NBA
  • Work with us
  • Contact Us
  • Data and reporting
  • Freedom of information
  • Public interest disclosure
  • Resources
  • Accessibility
  • Privacy
  • Copyright
  • Disclaimer
  • BloodPortal Terms and Conditions of Use

Information

  • Blood Products
  • Managing blood supply
  • Supply systems
  • Clinical guidance
  • Patient information
  • Data and research
  • Website feedback